MedTrace Logo

Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia

NCT07146542 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2025-08-28

No results posted yet for this study

Summary

The goal of this study is to understand how the protein CD81 affects myeloid leukemia (especially AML) and whether it can help predict patient outcomes or guide treatment.

The main question it aims to answer:

Is high CD81 expression in myeloid leukemia cells linked to more aggressive disease, poorer treatment response, or shorter survival in patients?

Participants:

* Newly diagnosed myeloid leukemia patients (primary focus on AML)
* Bone marrow or blood samples will be collected during routine diagnostic procedures

Conditions

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2028-03-31
Completion
2028-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07146542 on ClinicalTrials.gov